The Akt Antagonist Azd5363 Suppresses Features Associated with Cancer Progression in Human Larynx Cancer Cells

Abstract

Objectives: Larynx cancer (LCa) represents approximately 30% of all cancers seen in the head and neckregion, with an unchanged overall survival rate over the last decades. Although several novel diagnostic andtherapeutic options has been developed, an effective treatment strategy is not currently available due to thehigh metastatic and recurrent potential of LCa. In this study, we aimed at investigating the inhibitory potentialof AZD5363 on the phenotypes associated with LCa progression in vitro.Methods: The impacts of AZD5363 on the proliferation, colony formation, and apoptosis potentials of HEp2 cells were tested using Cell Viability Detection Kit-8, soft agar assay and Annexin V-FITC Apoptosis assay,respectively. Migration features of cells were evaluated using scratch and transwell migration assays.Results: We showed that AZD5363 increased phosphorylation of AKT and inhibited the phosphorylation ofits downstream effector GSK3β in an in vitro. LCa model in line with the findings of previous studies carriedout with different cancer types. Besides, AZD5363 successfully suppressed proliferative, clonogenic, andmigratory features of HEp-2 cells through induction of apoptosis.Conclusions: We revealed putative functions of AZD5363 in vitro. that points its potential to be used as anadjuvant agent against LCa. However, further comprehensive molecular and clinical research is needed toelucidate the potential use of AZD5363 in LCa therapy in detail.